ASM Global’s AO Arena in Manchester Unveils Dramatic Multimillion Dollar Three-Year Reimagination of Legendary Venue
27.4.2022 20:05:00 EEST | Business Wire | Press release
ASM Global, the world’s leading producer of entertainment experiences, venue management and event strategy, has announced a $63 million plan beginning this summer to transform the AO Arena in Manchester. This plan is set to dramatically enhance the venue’s premier position for live entertainment experiences through state-of-the-art infrastructure expansion and innovative guest features as the iconic arena looks to the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005883/en/
AO Arena, Manchester (Photo: Business Wire)
AO Arena in Manchester, located in the heart of the city, is one of the busiest indoor arenas in the world. Through its near 30-year history, the venue has firmly established itself as a beloved and iconic Manchester landmark, a must-play for artists, and a fan-favorite destination for world-class live entertainment. Officials from the AO Arena will be releasing more detailed plans in coming months.
Chris Bray, EVP Europe at ASM Global, said, “AO Arena is one of the world’s iconic venues and a much-loved part of Manchester’s rich culture and history. It has been delivering world-class entertainment experiences for over two decades. As we approach our 30th anniversary, this ambitious endeavor will not only reinforce its position as a leading destination for live entertainment but will extend its market leadership for ‘live’ and fan experiences for the next 30 years. We’re proud to be further investing into the heart of Manchester.
“The first phase will enhance and increase our standing floor capacity to share this historic arena with even more of our guests, and we will also be adding new hospitality lounges and investing in delivering an upgraded concourse experience. Our performers will be immersed in an all-new, back-of-house artists’ campus, unparalleled anywhere.”
Additional major developments include new arena entrances welcoming guests to the venue and new premium seating, which will transform the venue to an elevated experience.
AO Arena’s back-of-house campus dramatic upgrade will include a complete overhaul of the backstage experience for artists, production and crew. This includes new artist dressing rooms and production areas, a world-class green room with meet-and-greet facilities, an overhaul of crew catering, and first-class connectivity and technology.
Plans have already been jump started by the venue’s rapid scheduling of major sell-out 2022 events, including Billie Eilish, Dua Lipa, Diana Ross, Alicia Keys, Swedish House Mafia, Snoop Dogg, George Ezra and more.
Jen Mitchell, general manager at the AO Arena, said, “This is a really exciting time for AO Arena. Not only are we able to welcome guests back after a challenging two years with a program packed full of world-class acts and entertainment, now we can reveal the first phase of ASM Global’s plans for the arena’s redevelopment. This will enhance the experience for everyone who sets foot in the venue, including artists, production, crew and our staff who work so hard to make the magic happen right here in Manchester.”
Unveiled in 1995, the arena was the first indoor venue in the U.K. to be built with a layout of 360-degree seating. Attracting over 1 million visitors yearly, the 21,000-capacity arena is a winner of the Stadium Business Awards’ prestigious ‘Venue of the Year’ award. There has been a host of musical talent that has performed at the venue, from Led Zeppelin legends Jimmy Page and Robert Plant, The Rolling Stones and Pavarotti to Dua Lipa and Lady Gaga as well as Manchester’s homegrown artists including Take That, Oasis, Elbow, New Order and The Courteeners. The venue has hosted everything from the 2002 Commonwealth Games, 2008 FINA World Swimming Championships and international boxing bouts by Mike Tyson, Anthony Joshua, Tyson Fury, David Haye, Joe Calzaghe and local champions Ricky Hatton, Amir Khan and Anthony Crolla.
About ASM Global
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Connect with us on LinkedIn, Facebook, Instagram and Twitter. asmglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005883/en/
Contact information
Jim Yeager
breakwhitelight (for ASM Global)
jim@breakwhitelight.com
Mobile: 1-818-264-6812
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom